The present disclosure relates to novel solid pharmaceutical formulations and process for their preparation. The present disclosure also provides, in part, methods of using the pharmaceutical formulations for regulating the expression of apolipoprotein A-I (ApoA-I), and their use for the treatment a
The present disclosure relates to novel solid pharmaceutical formulations and process for their preparation. The present disclosure also provides, in part, methods of using the pharmaceutical formulations for regulating the expression of apolipoprotein A-I (ApoA-I), and their use for the treatment and prevention of cardiovascular disease and related disease states, including cholesterol- or lipid-related disorders, such as, for example, atherosclerosis.
대표청구항▼
1. A method for treating a cardiovascular-, cholesterol-, or lipid-related disease or disorder, comprising administering a pharmaceutical formulation comprising an active ingredient selected from: 2-(4-(2-hydroxyethoxy)-3,5-dimethylphenyl)-5,7-dimethoxyquinazolin-4(3H)-one;and pharmaceutically accep
1. A method for treating a cardiovascular-, cholesterol-, or lipid-related disease or disorder, comprising administering a pharmaceutical formulation comprising an active ingredient selected from: 2-(4-(2-hydroxyethoxy)-3,5-dimethylphenyl)-5,7-dimethoxyquinazolin-4(3H)-one;and pharmaceutically acceptable salts, stereoisomers, hydrates, and tautomers thereof: wherein the active ingredient is present: (a) in an amount front about 10% to about 12% by weight and the formulation further comprises: (i) about 82% to about 83% by weight of microcrystalline cellulose;(ii) about 2.5% by weight of colloidal silicon dioxide;(iii) about 4.0% by weight of sodium starch glycolate; and(iv) about 0.5% by weight of magnesium stearate;(b) in an amount from about 20% to about 22% by weight and the formulation further comprises: (i) about 70% to about 72% by weight of microcrystalline cellulose;(ii) about 2.5% by weight of colloidal silicon dioxide;(iii) about 4.0% by weight of sodium starch glycolate; and(iv) about 0.5% by weight of magnesium stearate;(c) in an amount from about 31% to about 33% by weight and the formulation further comprises: (i) about 60% to about 62% by weight of microcrystalline cellulose;(ii) about 2.5% by weight of colloidal silicon dioxide;(iii) about 4.0% by weight of sodium starch glycolate; and(iv) about 0.5% by weight of magnesium stearate; or (d) in an amount from about 41% to about 43% by weight and the formulation further comprises: (i) about 50% to about 51% by weight of microcrystalline cellulose;(ii) about 2.5% by weight of colloidal silicon dioxide;(iii) about 4.0% by weight of sodium starch glycolate; and(iv) about 0.5% by weight of magnesium stearate; and wherein the formulation is formulated for oral administration and immediate release. 2. The method of claim 1, wherein the active ingredient is the hydrochloride salt of 2-(4-(2-hydroxyethoxy)-3,5-dimethylphenyl)-5,7-dimethoxyquinazolin-4(3H)-one. 3. The method of claim 1, wherein the active ingredient has a particle size from about 1-250 microns, about 1-100 microns, or about 1-10 microns. 4. The method of claim 1, wherein the formulation comprises from about 25-100 mg of the active ingredient. 5. The method of claim 4, wherein the active ingredient is present in the formulation in an amount selected from about 25, 50, 75, or 100 mg. 6. The method of claim 1, wherein the formulation has a disintegration time of 120 seconds or less. 7. The method of claim 1, wherein the cardiovascular-, cholesterol-, or lipid-related disease or disorder is selected from acute coronary syndrome, angina, arteriosclerosis, atherosclerosis, carotid atherosclerosis, cerebrovascular disease, cerebral infarction, congestive heart failure, congenital heart disease, coronary heart disease, coronary artery disease, coronary plaque stabilization, dyslipidemias, dyslipoproteinemias, endothelium dysfunctions, familial hypercholeasterolemia, familial combined hyperlipidemia, hypoalphalipoproteinemia, hypertriglyceridemia, hyperbetalipoproteinemia, hypercholesterolemia, hypertension, hyperlipidemia, intermittent claudication, ischemia, ischemia reperfusion injury, ischemic heart diseases, cardiac ischemia, multi-infarct dementia, myocardial infarction, obesity, peripheral vascular disease, reperfusion injury, restenosis, renal artery atherosclerosis, rheumatic heart disease, stroke, thrombotic disorder, transitory ischemic attacks, syndrome X, impotence, multiple sclerosis, and Parkinson's disease. 8. The method of claim 1, wherein the cardiovascular-, cholesterol-, or lipid-related disease or disorder is metabolic syndrome. 9. The method of claim 1, wherein the cardiovascular-, cholesterol-, or lipid-related disease or disorder is Alzheimer's disease. 10. The method of claim 1, wherein the cardiovascular-, cholesterol-, or lipid-related disease or disorder is diabetes mellitus. 11. The method of claim 10, wherein the diabetes mellitus is associated with a disease selected from hyperglycemia, hyperinsulinemia, hyperlipidemia, insulin resistance, impaired glucose metabolism, obesity, diabetic retinopathy, macular degeneration, cataracts, diabetic nephropathy, glomerulosclerosis, erectile dysfunction, premenstrual syndrome, vascular restenosis, ulcerative colitis, skin and connective tissue disorders, foot ulcerations, metabolic acidosis, arthritis, osteoporosis and impaired glucose tolerance. 12. A method for treating a cancer selected from midline carcinoma, aggressive human medulloblastoma, hematological cancer, lung cancer, breast cancer, colon carcinomas, and hepatic tumors, comprising administering a pharmaceutical formulation comprising an active ingredient selected from: 2-(4-(2-hydroxyethoxy)-3,5-dimethyphenyl)-5,7-dimethoxyquinazolin-4(3H)-one;and pharmaceutically acceptable salts, stereoisomers, hydrates, and tautomers thereof; wherein the active ingredient is present: (a) in an amount from about 10% to about 12by weight and the formulation further comprises: (i) about 82% to about 83% by weight of microcrystalline cellulose;(ii) about 2.5% by weight of colloidal silicon dioxide;(iii) about 4.0% by weight of sodium starch glycolate; and(iv) about 0.5% by weight of magnesium stearate;(b) in an amount from about 20% to about 22% by weight and the formulation further comprises: about 70% to about 72% by weight microcrystalline cellulose;about 2.5% by weight of colloidal silicon dioxide;about 4.0% by weight of sodium starch glycolate; andabout 0.5% by weight of magnesium stearate;(c) in an amount from about 31% to about 33% by weight and the formulation further comprises: (i) about 60% to about 62% by weight of microcrystalline cellulose;(ii) about 2.5% by weight of colloidal silicon dioxide;(iii) about 4.0% by weight of sodium starch glycolate; and(iv) about 0.5% by weight of magnesium stearate; or (d) in an amount from about 41% to about 43% by weight and the formulation further comprises: (i) about 50% to about 51% by weight of microcrystalline cellulose;(ii) about 2.5% by weight of colloidal silicon dioxide;(iii) about 4.0% by weight of a sodium starch glycolate; and(iv) about 5% by weight of magnesium stearate; and wherein the formulation is formulated for oral administration and immediate release. 13. The method of claim 12, wherein the hematological cancer is selected from Burkitt's lymphoma, acute myelogenous leukemia, and multiple myeloma. 14. A method for treating an IL-6 mediated inflammatory disease, comprising administering a pharmaceutical formulation comprising an active ingredient selected from: 2-(4-(2-hydroxyethoxy)-3,5-dimethylphenyl)-5,7-dimethoxyquinazolin-4(3H)-one;and pharmaceutically acceptable salts, stereoisomers, hydrates, and tautomers thereof; wherein the active ingredient is present: (a) in an amount from about 10% to about 12% by weight and the formulation further comprises: (i) about 82% to about 83% by weight of microcrystalline cellulose;(ii) about 2.5%, by weight of colloidal silicon dioxide;(iii) about 4.0% by weight of sodium starch glycolate; and(iv) about 0.5% by weight of magnesium stearate;(b) in an amount from about 20% to about 22% by weight and the formulation further comprises: (i) about 70% to about 72% by weight of microcrystalline cellulose;(ii) about 2.5% by weight of colloidal silicon dioxide;(iii) about 4.0% by weight of sodium starch glycolate; and(iv) about 0.5% by weight of magnesium stearate;(c) in an amount from about 31% to about 33% by weight and the formulation further comprises: (i) about 60% to about 62% by weight of microcrystalline cellulose;(ii) about 2.5% by weight of colloidal silicon dioxide;(iii) about 4.0% by weight of sodium starch glycolate; and(iv) about 0.5% by weight of magnesium stearate; or (d) in an amount from about 41% to about 43% by weight and the formulation further comprises: (i) about 50% to about 51% by weight of microcrystalline cellulose;(ii) about 2.5% by weight of colloidal silicon dioxide;(iii) about 4.0% by weight of sodium starch glycolate; and(iv) about 0.5% by weight of magnesium stearate; and wherein the formulation is formulated for oral administration and immediate release. 15. A method for treating a bacterial infection or a viral infection selected from human immunodeficiency virus (HIV), herpes virus, and papilloma virus, comprising administering a pharmaceutical formulation comprising an active ingredient selected from: 2-(4-(2-hydroxyethoxy)-3,5-dimethylphenyl)-5,7-dimethoxyquinazolin-4(3H)-one;and pharmaceutically acceptable salts, stereoisomers, hydrates, and tautomers thereof; wherein the active ingredient is present: (a) in an amount from about 10% to about 12% by weight and the formulation further comprises: (i) about 82% to about 83% by weight of microcrystalline cellulose;(ii) about 2.5% by weight of colloidal silicon dioxide;(iii) about 4.0% by weight of sodium starch glycolate; and(iv) about 0.5% by weight of magnesium stearate;(b) in an amount from about 20% to about 22% by weight and the formulation further comprises: (i) about 70% to about 72% by weight of microcrystalline cellulose;(ii) about 2.5% by weight of colloidal silicon dioxide;(iii) about 4.0% by weight of sodium starch glycolate; and(iv) about 0.5% by weight of magnesium stearate;(c) in an amount from about 31% to about 33% by weight and the formulation further comprises: (i) about 60% to about 62% by weight of microcrystalline cellulose;(ii) about 2.5% by weight of colloidal silicon dioxide;(iii) about 4.0% by weight of sodium starch glycolate; and(iv) about 0.5% by weight of magnesium stearate; or (d) in an amount from about 41% to about 43% by weight and the formulation further comprises: (i) about 50% to about 51% by weight of microcrystalline cellulose;(ii) about 2.5% by weight of colloidal silicon dioxide;(iii) about 4.0% by weight of sodium starch glycolate; and(iv) about 0.5% by weight of magnesium stearate;and wherein the formulation is formulated for oral administration and immediate release.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (84)
Sheng-Chu Kuo TW; Mann-Jen Hour TW; Li-Jiau Huang TW; Kuo-Hsiung Lee, 2-phenyl-4-quinazolinone compounds, 2-phenyl-4-alkoxy-quinazoline compounds and their pharmaceutical compositions.
Blankley Clifton John ; Doherty Annette Marian ; Hamby James Marino ; Panek Robert Lee ; Schroeder Mel Conrad ; Showalter Howard Daniel Hollis ; Connolly Cleo, 6-Aryl pyrido[2,3-d] pyrimidines and naphthyridines for inhibiting protein tyrosine kinase mediated cellular proliferat.
Klunk William E. ; Pettegrew Jay W. ; Mathis ; Jr. Chester A., Alkyl, alkenyl and alkynyl Chrysamine G derivatives for the antemortem diagnosis of Alzheimer's disease and in vivo imaging and prevention of amyloid deposition.
Dressel Jrgen (Wuppertal DEX) Fey Peter (Wuppertal DEX) Hanko Rudolf H. (Dsseldorf DEX) Hbsch Walter (Wuppertal DEX) Krmer Thomas (Wuppertal DEX) Mller Ulrich E. (Wuppertal DEX) Mller-Gliemann Matthi, Biphenylmethyl-substituted pyridones.
Spada Alfred P. (Lansdale PA) Maquire Martin P. (King of Prussia PA) Persons Paul E. (King of Prussia PA) Myers Michael R. (Reading PA), Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase.
Spada Alfred P. (Lansdale PA) Myers Michael R. (Reading PA) Maguire Martin P. (Mont Clare PA) Persons Paul E. (King of Prussia PA), Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase.
Albrecht, Brian K.; Audia, James Edmund; Côté, Alexandre; Gehling, Victor S.; Harmange, Jean-Christophe; Hewitt, Michael Charles; Leblanc, Yves; Nasveschuk, Christopher G.; Taylor, Alexander M.; Vaswani, Rishi G., Bromodomain inhibitors and uses thereof.
Bisgaier Charles Larry ; Creger Paul Leroy ; Saltiel Alan Robert ; Tafuri Sherrie Rae, Carboxyalkylethers, formulations, and treatment of vascular diseases.
Guthrie Najla,CAX ; Kurowska Elzbieta Maria,CAX, Compositions and methods for treatment of neoplastic diseases with combinations of limonoids, flavonoids and tocotrienols.
Stein Bernd M. ; Anderson David Wesley ; Gayo-Fung Leah M. ; Sutherland May S. ; Doubleday Mary ; Shevlin Graziella I. ; Kois Adam ; Khammungkhune Sak ; Jalluri Ravi Kumar ; Bhagwat Shripad S. ; McKi, Compounds and methods for modulation of estrogen receptors.
Magarian Robert A. (Norman OK) Pento Joseph T. (Norman OK) Avor Kwasi S. (Columbia MO), Diphenylcyclopropyl analogs as antiestrogenic and antitumor agents.
Wong, Norman C. W.; Tucker, Joseph E. L.; Hansen, Henrik C.; Chiacchia, Fabrizio S.; McCaffrey, David, Flavanoids and isoflavanoids for the prevention and treatment of cardiovascular diseases.
Wong, Norman C. W.; Tucker, Joseph E. L.; Hansen, Henrik C.; Chiacchia, Fabrizio S.; McCaffrey, David, Flavanoids and isoflavanoids for the prevention and treatment of cardiovascular diseases.
Bok Song-Hae,KRX ; Son Kwang-Hee,KRX ; Jeong Tae-Sook,KRX ; Kwon Byoung-Mog,KRX ; Kim Young-Kook,KRX ; Choi Doil,KRX ; Kim Sung-Uk,KRX ; Bae Ki-Hwan,KRX ; Park Yong-Bok,KRX ; Choi Myung-Sook,KRX ; Hw, Hesperidin and hesperetin as 3-hydroxy-3-methylglutaryl CoA (HMG-CoA) reductase inhibitor.
Bolland Yves (Vanves FRX) Lewin Guy (Rueil Malmaison FRX) Vilaine Jean-Paul (Chatenay Malabry FRX) Lenaers Albert (Triel sur Seine FRX) Thollon Catherine (Paris FRX), Medicinal use of 3′,5′-di-tert.-butyl-4′-hydroxy flavones.
Hansen, Henrik C.; Chopade, Shubham P.; Citineni, Janakiram R.; Short, Robert P.; Yiannikouros, George P., Methods of preparing quinazolinone derivatives.
Wong, Norman C. W.; Hansen, Henrik C.; Chiacchia, Fabrizio S.; Johansson, Jan O., Pharmaceutical compositions for the prevention and treatment of complex diseases and their delivery by insertable medical devices.
John M. Pezzuto ; Richard C. Moon ; Mei-Shiang Jang ; Aomar Ouali CA; Shengzhao Lin CA; Karla Slowing Barillas ES, Pharmaceutical formulations of resveratrol and methods of use thereof.
Wong, Norman C. W.; Tucker, Joseph E. L.; Hansen, Henrik C.; Chiacchia, Fabrizio S.; McCaffrey, David, Stilbenes and chalcones for the prevention and treatment of cardiovascular diseases.
Wong, Norman C. W.; Tucker, Joseph E. L.; Hansen, Henrik C.; Chiacchia, Fabrizio S.; McCaffrey, David, Stilbenes and chalcones for the prevention and treatment of cardiovascular diseases.
Schindler, Ursula; Schonafinger, Karl; Strobel, Hartmut; Schindler, Peter, Substituted 2-aryl-4-amino-chinazolines, method for the production and use thereof as medicaments.
Dressel Jrgen (Wuppertal DEX) Fey Peter (Wuppertal DEX) Hanko Rudolf H. (Dsseldorf DEX) Hbsch Walter (Wuppertal DEX) Krmer Thomas (Wuppertal DEX) Mller Ulrich E. (Wuppertal DEX) Mller-Gliemann Matthi, Sulfonylbenzyl-substituted benzo- and pyridopyridones.
Rouy, Didier; Duverger, Nicolas; Emmanuel, Florence; Denefle, Patrice; Houdebine, Louis-Marie; Viglietta, Celine; Rubin, Edward M.; Hughes, Steven D., Transgenic rabbit that expresses a functional human lipoprotein (a).
※ AI-Helper는 부적절한 답변을 할 수 있습니다.